Critical Outcome Technologies Inc.  

(Public, CVE:COT)   Watch this stock  
Find more results for cve:cot
0.290
+0.030 (11.54%)
Jul 27 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.27 - 0.29
52 week 0.20 - 0.38
Open 0.28
Vol / Avg. 36,000.00/48,861.00
Mkt cap 35.33M
P/E     -
Div/yield     -
EPS -0.05
Shares 121.83M
Beta -0.08
Inst. own     -

Key stats and ratios

Q1 (Jan '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -120.95% -125.25%
Return on average equity -170.21% -177.54%
Employees 10 -
CDP Score - -

Address

213 - 700 Collip Circle
LONDON, ON N6G 4X8
Canada
+1-519-8585157 (Phone)
+1-519-8585179 (Fax)

Website links

Description

Critical Outcome Technologies Inc. (COTI) is a Canada-based biotechnology company focused on applying its computer-based technology, CHEMSAS, to identify, profile, optimize and select potential new drug candidates at the discovery stage of preclinical drug development. COTI is concentrated on developing drug candidates for the treatment of various cancers, human immunodeficiency virus (HIV), Alzheimer’s disease and multiple sclerosis. Cancer types specifically targeted include small cell lung cancer, adult myelogenous leukemia (AML), ovarian, endometrial, pancreatic, brain, breast and colorectal cancer. COTI-2 is a novel small molecule that acts by inhibiting Akt/PKB (Protein kinase B) phosphorylation that leads to caspase-9 activation in cancer cells. The Company also seeks to leverage CHEMSAS to identify targeted lead candidates of commercial interest to pharmaceutical, biotechnology, research, and academic organizations on a collaborative basis.

Officers and directors

John C. Drake Independent Chairman of the Board
Wayne R. Danter M.D. President, Chief Executive Officer, Chief Scientific Officer, Director
Gene Kelly Chief Financial Officer
Douglas S. Alexander Independent Director
Bruno C. Maruzzo Independent Director
Age: 61
Dave Sanderson Independent Director
Alison Silva Independent Director